Experts in prostate cancer discuss considerations for initiating ADT therapy after definitive treatment in patients with prostate cancer in the context of biochemical recurrence.
The median duration of CR in those who experienced a response to treatment was 26.6 months (95% CI, 9.9-not reached [NR]).
“At a time when patients are increasingly concerned about prescription drugs, this information will provide a useful starting point for making essential medications as affordable…
“Alpha-blockers are often, for patients, the first line of treatment because they help quickly relax the smooth muscles in the bladder and the prostate,” says…
“I cannot overstate the impact of this device on my management of kidney stone patients,” says J. Stuart Wolf, Jr., MD, FACS.
“This preplanned ENACT trial biomarker analysis demonstrates the value of the Decipher score, AR-A score, and PAM50 genomic classifiers in identifying patients undergoing AS who…
“For those who do enucleations, I think I would encourage people to highly consider adopting an apical release technique if they haven’t,” says Daniel J.…
“The advance of PSMA imaging has put an emphasis on multidisciplinary care,” says Kenneth J. Pienta, MD.
“In the future, this imaging technique can help to streamline the drug development process, driving conviction in the agents we bring to larger scale trials,”…
The IND will initiate the launch of a phase 3 study to explore the safety and efficacy of UGN-103 in patients with low-grade, intermediate-risk NMIBC.
The 3 new additional studies are the ABLE-22, ABLE-32, and ABLE-42 clinical trials.
